3-o-methyl-6-fluoro-dopa has been researched along with Parkinson Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandez, HH; Friedman, JH | 1 |
| de la Fuente-Fernandez, R; Holden, JE; Ruth, TJ; Sossi, V; Stoessl, AJ | 1 |
| Aalto, S; Brück, A; Forsback, S; Jokinen, P; Parkkola, R; Rinne, JO | 1 |
| Cumming, P; Gjedde, A; Kuwabara, H; Léger, GC | 1 |
| Belakhlef, A; Chaly, T; Dhawan, V; Eidelberg, D; Ishikawa, T; Mandel, F; Margouleff, C; Patlak, C; Robeson, W | 1 |
| Chaly, T; Dahl, JR; Dhawan, V; Eidelberg, D; Ishikawa, T; Mandel, F; Margouleff, C; Robeson, W; Spetsieris, P | 1 |
| Nahmias, C; Wahl, L | 1 |
| Barrio, JR; Huang, SC; Namavari, M; Satyamurthy, N; Stout, DB; Yee, RE | 1 |
8 other study(ies) available for 3-o-methyl-6-fluoro-dopa and Parkinson Disease
| Article | Year |
|---|---|
18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson disease.
Topics: Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Humans; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Reference Values; Severity of Illness Index | 2003 |
Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.
Topics: Aged; Analysis of Variance; Atrophy; Caudate Nucleus; Cognition Disorders; Dihydroxyphenylalanine; Dopamine; Female; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Statistics, Nonparametric | 2009 |
Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans.
Topics: Adult; Arteries; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Parkinson Disease; Reference Values; Tomography, Emission-Computed | 1993 |
Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Topics: Adult; Blood-Brain Barrier; Brain; Case-Control Studies; Corpus Striatum; Decarboxylation; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Models, Biological; Parkinson Disease; Time Factors; Tomography, Emission-Computed | 1996 |
Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Topics: Brain; Case-Control Studies; Corpus Striatum; Dihydroxyphenylalanine; Dopa Decarboxylase; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Models, Biological; Parkinson Disease; Tomography, Emission-Computed | 1996 |
Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
Topics: Adult; Biological Transport; Blood-Brain Barrier; Case-Control Studies; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Humans; Male; Middle Aged; Models, Biological; Parkinson Disease; Time Factors; Tomography, Emission-Computed | 1996 |
Distribution volume of 3-O-methyl-6.
Topics: Amino Acids, Neutral; Animals; Blood-Brain Barrier; Brain; Cerebellum; Corpus Striatum; Dihydroxyphenylalanine; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tomography, Emission-Computed | 2000 |